Browse Studies — Arctuva

Phase 3

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progres…

Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive

Estimated

~$10 – $8,750

Nuvalent Inc.NCT06765109

Phase 1

A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in…

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive

Estimated

~$10 – $8,750

Astellas Pharma Global Development, Inc.NCT07140016

Phase 1

A Phase I Study of Alectinib Plus Duvelisib in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ ALCL)

The researchers are doing this study to see if alectinib in combination with duvelisib is a safe and effective time-limited treatment for people with relapsed …

Anaplastic Lymphoma KinaseAnaplastic Large Cell Lymphoma

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07001384

Phase 1

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. r…

Advanced CancerAdvanced Solid TumorMelanoma+15 more

Estimated

~$10 – $8,750

7 Hills Pharma, LLCNCT06362369